Drug Approval | January 28, 2023
USFDA provides exception to Glenmark's Baddi facility
The company will engage with the agency to resolve the import alert at the earliest.
The company will engage with the agency to resolve the import alert at the earliest.
SEZABY is a benzyl alcohol-free and propylene glycol-free formulation of phenobarbital sodium powder for injection
Cell sorting technology supports researchers advancing new therapies
OmiCrisp has been developed with support from Centre for Cellular And Molecular Platforms C-CAMP-InDx Program
Medical Tourism will boost India’s economy
Asthma patients are more likely to have an asthma attack during winter
It is administered as a single infusion 30 minutes prior to the start of each chemotherapy cycle that helps prevent, both, acute and delayed phases of CINV
The company is pleased to report positive performances from all divisions this quarter. Growth in our research divisions, Discovery Services and the Dedicated Centres was solid
The company is adding new capabilities of Combi-line for Microsphere, additional Bag line and lyos for the Penem block in Pashamylaram facility in Hyderabad and will be earmarking capital for further building on its Biosimilar CDMO facility
The supplemental New Drug Application is based on results from the landmark EMPA-KIDNEY phase III trial
Subscribe To Our Newsletter & Stay Updated
